HIV has basic structural features similar to lentiviruses. It is assembled by the coat protein (p24) to form the core. On its outer side, it is formed by matrix proteins (p17). The outermost part is encapsulated by a lipid-like membrane studded with envelope (Env) gp120 and gp41. The primary function of gp120 is to bind to co-receptors and CD4 receptors on the surface of the host cell. Gp41 mediates the fusion of the cell membrane with the viral envelope through a conformational change. Vaccines are one way to prevent HIV. Current research on HIV vaccines focuses on various aspects such as DNA vaccines. Env is formed by cleavage of the Env precursor gp160. The development of glycoprotein vaccines based on gp120, gp41, and gp160 is a hot research topic.
Fig.1 Structure of HIV. (Wikipedia)
CD BioGlyco has an advanced sugar-related Vaccine Development Platform and extensive experience in the development of vaccines. Env is a structurally complex Glycoprotein. We provide Env-based HIV vaccine development services, including cell biology mechanism of action studies, in vitro immunoassays, immunogenicity testing, stability testing, etc. Both in vitro and in vivo experiments can be accomplished.
We express various proteins mainly through genetic engineering. Env is expressed using Mammalian cells, Yeast Expression Systems, etc. Afterwards, we perform purification and evaluation experiments. Adjuvant addition enhances the immunogenicity of glycoprotein vaccines. We also provide adjuvant development services.
To improve the safety, immunogenicity, etc., of HIV vaccines, we modify and optimize the structure of Env as a way to induce broad-spectrum neutralizing antibodies. We integrate the sequences of different subtypes of the HIV-1 gene for comparison, retaining the bases that occur most commonly in them. The consensus sequences obtained in this way have a high degree of similarity to the sequences of the other HIV-1 genes analyzed. Envs designed as antigens using the consensus sequence are able to induce close or higher levels of conjugated antibody responses against different subtypes of HIV-1.
Fig.2 The process of HIV vaccine development. (CD BioGlyco)
CD BioGlyco is an excellent sugar-related vaccine development company. We have extensive experience in glycoprotein vaccine development. In addition to recombinant glycoprotein vaccines, we also provide Carbohydrate-based Vaccines, Glycopeptide Vaccine Development Services, etc. Welcome to contact us if you have any questions or suggestions about our products and services.
References
